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Abstract
Background: To evaluate the functional recovery of patients with symptomatic vitreomacular traction (VMT) after
Ocriplasmin treatment.
Methods: Prospective, single centre, consecutive case series. Patients were treated with a single intravitreal
injection of Ocriplasmin (Jetrea, Thrombogenics Inc, USA, Alcon/Novartis EU). The following outcome measures are
considered: resolution of VMT, evaluated through the use of optical coherence tomography (SD-OCT), functional
recovery evidenced by multifocal-electroretinogram (mfERG) and microperimetry (MP1) after treatment with
Ocriplasmin.
Results: Four eyes of four patients were treated with Ocriplasmin injection. We observed a VMT non-surgical
resolution in all patients. The longitudinal statistical analysis showed a significant improvement of best corrected
visual acuity (BCVA) in the treated eye of about 0.97 letters/week (p = 0.033). No significant difference was observed
in mean sensitivity (p > 0.05) assessed by MP1 in both eyes, while improvement in fixation stability was assessed in
treated eyes (β = 0.39; p = 0.029). In the four treated eyes mfERG revealed an increased foveal peak response over
the follow-up. The longitudinal analysis of mfERG data shows a significant increase of N1 and P1 amplitude in the
first rings and a significant decrease of N1 and P1 implicit time in most rings.
Conclusions: We report on four cases with resolution of VMT after Ocriplasmin treatment. Our preliminary results
demonstrate that Ocriplasmin is safe and effective in the treatment of VMT, because it not only leads to a morphological
recovery but mostly to a restoration of macular functionality, evaluated through the use of different objective tests, such
as MP1 and mfERG over a six-month follow-up.
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Background
The treatment of vitreomacular interface disorders,
including symptomatic vitreomacular adhesion (VMA),
vitreomacular traction (VMT), and evolving or early
macular hole (MH), has traditionally been treated by
vitreo-retinal surgery. Recently, Ocriplasmin (Jetrea;
Thrombogenics), a recombinant truncated form of human
serine protease plasmin with activity against components
of the vitreoretinal interface, including fibronectin and
laminin, was approved for the treatment of symptomatic
VMA [1]. When injected intravitreally, Ocriplasmin in-
duces vitreous liquefaction and separation of vitreoretinal
adhesions at the macula and peripapillary retina [2]. In
pivotal phase 3 clinical trials, a one-time intravitreal
injection of Ocriplasmin (125 μg per 100 μL) was adminis-
tered in treatment for symptomatic VMA including small
(less than or equal to 250 μm) and medium (250 to
400 μm) MH with persistent VMA [1]. When evaluating
the pooled data from the pivotal studies, the incidence of
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non-surgical resolution of VMA was found to be 26.5 %,
compared to 10.1 % with placebo injection [1].
Although the safety and clinical efficacy of Ocriplasmin
have been established in two phase 3 vehicle-controlled
clinical studies, the long-term effects of Ocriplasmin have
not been widely documented: recently some small case
series and case reports showed visual disturbances and/or
adverse events (e.g., acute severe panretinal dysfunction
[3], disruption of photoreceptor inner segment–outer seg-
ment [4]) after Ocriplasmin injection. The controversial
findings of the different studies and the limited number of
published cases require further evidence to show the
safety profile and effectiveness of Ocriplasmin. Moreover,
the studies in the literature analyzed the visual recovery of
patients undergoing Ocriplasmin injection by assessing
visual acuity, [1, 5–7] full-field electroretinogram (ERG),
[3, 4, 8] and morphological recovery on optical coherence
tomography (OCT) scans [1, 5–7]. Finally, only two recent
clinical cases showed functional findings before and after
Ocriplasmin injection evaluated by multifocal electro-
retinogram (mfERG) [4, 9].
The purpose of the current study is to provide more
evidence about safety profile and clinical effectiveness
of Ocriplasmin, by reporting a case series of four pa-
tients treated by Ocriplasmin injection for symptomatic
VMT and MH in our University Hospital. We assessed
the effect of treatment by conventional morphologic
tests (i.e., OCT). Furthermore, for the first time in the
literature, we evaluated macular functionality through
the study of tests such as Microperimetry (MP1) and
mfERG over a six month follow-up.
Methods
After the approval of Ocriplasmin for VMT in March
2013, we injected Ocriplasmin in a group of four patients
(four eyes). Inclusion criteria were: age over 18 years, adhe-
sion diameter less than 1,500 μm, presence of natural lens,
absence of epiretinal membrane, and alteration in visual
functionality (i.e., BCVA reduction, metamorphopsia) in
the eye to be treated. After dilution with 0.2 mL of sodium
chloride 9 mg/mL (0.9 %) solution for injection, 0.1 mL of
the diluted solution, containing 125 μg of Ocriplasmin,
was injected into the vitreous. All patients received peri-
bulbar anaesthesia and each injection was performed with
observation of ocular fundus in order to inject the medica-
tion as close as possible to the optic disk. Each patient was
examined at baseline and follow-up visits were scheduled
at one, two, four weeks, three months and six months.
Each visit included best corrected visual acuity (BCVA)
measurement, spectral domain optical coherence tom-
ography (SD-OCT) and, from the second week of
follow-up, also mfERG and MP1. The study adhered to
the tenets of the Declaration of Helsinki and received
approval by the Local Ethics Committee of the Second
University of Naples. Moreover, each patient gave
written informed consent.
BCVA was measured by using ETDRS charts. Meta-
morphopsia was assessed by Amsler grid test. OCT
was performed with Cirrus HD-OCT (Carl Zeiss,
Dublin, CA). The acquisition protocol comprised both
a five-line raster scan and a macular cube scan
pattern (512x128 pixels) in which a 6 x 6-mm region
of the retina was scanned within a scan time of 2.4 s.
MP1 was performed by an automatic fundus-related
perimeter (MP1 Microperimeter, Nidek Technologies,
Padova, Italy). The following parameters were used: a
fixation target of 2° in diameter consisting of a red
ring; a white, monochromatic background with a
luminance of 1.27 cd/m2; a Goldman III–size stimu-
lus with a projection time of 200 ms; and predefined
automatic macular test pattern covering 6° centred
onto the gravitational centre of all the fixation points with
43 stimuli. The mfERG responses from the treated eyes of
the subjects were performed using VERIS (Version 3, EDI,
CA, US) according to the guidelines of the International
Society for Clinical Electrophysiology of Vision [10]. The
implicit time and amplitude of N1 and P1 waves were
computed and analyzed.
Continuous variables are expressed as mean ± standard
deviation. A longitudinal analysis of clinical parameters
(i.e. BCVA, MP1 parameters and mfERG responses), was
performed by repeated measure regression models esti-
mated using Generalized Estimating Equations (GEE),
since GEE enable to deal with correlated data (such as
longitudinal data) also in small size clinical trials [11–13].
Relationship between BCVA and mfERG response param-
eter was investigated by regression models estimated by
GEE. For the regression models, the correlation coefficients
β, which express the mean estimated change of the param-
eter per week over the follow-up, are provided. A p-value
less than 5 % was considered statistically significant.
Results
Table 1 describes the main clinical and demographic pa-
rameters of the study subjects. A total of 4 consecutive pa-
tients with symptomatic VMT were treated with
intravitreal Ocrisplasmin injections by one retina specialist.
In one patient VMT was associated with a full-thickness
MH, while the remaining three patients had only VMT.
The mean age was 67.2 ± 1.3 years (from 64 to 69 years).
There were no cases of post-injection uveitis, endophthal-
mitis, retinal tears, or retinal detachment throughout the
follow-up period.
We observed a VMT non-surgical resolution in all
patients as shown by Fig. 1, which reports the OCT
scans before and after VMT resolution at six months
post-treatment. VMT release occurred within 1 week in
patient 3, within 2 weeks in patient 1, and within 4 weeks
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Table 1 Clinical and demographic parameters of the included subjects








Day of VMT Release
after the therapy
1 64 F phakic no 372 20/160 20/80 yes 14
2 69 F phakic no 682 20/63 20/50 yes 28
3 68 F phakic no 408 20/40 20/25 yes 7









Fig. 1 Baseline and post-operative OCT scans (after six months) in all treated subjects. The selected OCT scans show the release of VMT post-treatment
in all patients. In patient 1, we observed an enlargement of the full-thickness macular hole
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in patient 2 and patient 4. Moreover, we observed a
significant decreasing trend (p < 0.001) in the foveal
thickness, assessed on foveal OCT scans, at an estimated
linear rate of −44.3 μm per year. However, the Ocriplas-
min injection did not achieve the closure of the MH in
patient 1, which worsened from stage 2 to stage 4. Ex-
cept patient 1, we did not observe disruption of the
photoreceptor inner segment-outer segment ellipsoid in
any of the OCT scans after the injection of Ocriplasmin.
In the treated eyes, the average BCVA increased from
48 ± 19 ETDRS letters (equivalent to 20/63) at baseline
to 56 ± 14 ETDRS letters (equivalent to 20/40) at the six
month post-treatment time-point, whereas BCVA
remained stable in the untreated eyes (average at
baseline and the last time-point: 36 ± 23 ETDRS letters,
equivalent to 20/100). In particular, in the first three
patients, we observed an improvement of BCVA in the
treated eyes of at least one ETDRS line (six months),
while in the fourth patient BCVA was of 10/10 at the
baseline and remained stable over the follow-up and
metamorphopsia disappeared. The longitudinal statistical
analysis showed a significant improvement of BCVA in
the treated eyes of about 0.975 letters/week (p = 0.033),
while BCVA remained stable in the untreated eyes
(baseline: 36 ± 22 ETDRS letters; last time-point: 35 ± 23
ETDRS letters; p = 0.25). In particular, we observed that
BCVA declined after injection (average: 4 ± 1 ETDRS
letters) and started to improve after the resolution of
VMT (Fig. 2). We observed the smallest BCVA improve-
ment (4 ETDRS letters) in patient 2, who required the
longest time for VMT release (1 month).
Macular sensitivity, assessed by MP1, increased only in
the treated eyes of two patients, 2 and 4 (Table 2), while
fixation stability improved in three patients. The longitu-
dinal analysis showed no significant difference in macular
sensitivity in both treated (baseline: 12.7 ± 6.9 dB; last
time-point: 11.3 ± 8.3 dB; p = 0.16) and untreated eyes
(baseline: 10.3 ± 5.0 dB; last time-point: 11.4 ± 3.1 dB;
p = 0.81). As regards fixation stability, a significant
improvement of the percentage of fixation points
within the 4° circle was assessed in the treated eyes
(baseline: 57.8 ± 45.3 %; last time-point: 81.8 ± 20.8 %;
β = 0.39; p = 0.029), even if the trend of increased per-
centage of fixation points within the 2° circle was not
significant (baseline: 38.7 ± 41.7 %; last time-point:
57.7 ± 34.1 %; β = 1.03; p = 0.061).
Fig. 2 Time courses of BCVA over the 6-month follow-up. In the first three patients BCVA, following an initial decline, improved after the release of
VMT; in the last patient the BCVA remained stable (20/20) over all the follow-up
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mfERG revealed a progressive increased foveal peak
response in the treated eyes over the follow-up, as
shown in the first order response density at baseline
and at successive time-points, reported in Fig. 3.
Additional file 1 reports the data of mfERG responses at
the different time-points. The longitudinal analysis, re-
ported in Table 3, showed a significant decrease of N1 im-
plicit time in all the rings but the foveal one, of N1
amplitude in the first two rings, of P1 implicit time in the
first three rings, and a significant increase of P1 amplitude
in the first two rings. Finally, we observed a significant re-
lationship between BCVA and mfERG responses, in par-
ticular: a positive correlation with amplitude of P1 peak
(β = 1.406; p < 0.001) and amplitude of N1 peak (β =
1.302; p < 0.001); and a negative correlation with the P1
implicit time (β = −0.088; p = 0.004).
Discussion
Intravitreal injection of Ocriplasmin represents a
novel treatment option supplementing observation
and vitrectomy in the management of patients with
symptomatic vitreomacular interface disorders. In our
study, we report a case series of four patients treated with
injection of Ocriplasmin and we evaluate the release of
VMT not only from the morphological but also functional
standpoint. We observed an overall incidence of success-
ful VMT release (100 %), that was much higher compared
to the results of the MIVI-TRUST (MIVI-006, MIVI-007)
clinical trials (26.5 %) [1]. This could be explained by the
accurate selection of the patients with three independent
characteristics, which were shown to be associated with a
more favourable outcome, i.e., absence of epiretinal
membrane, adhesion diameter less than 1,500 μm,
Table 2 Comparison of micriperimetric features between baseline and the last post-treatment time-points
Id Treated eyes Untreated eyes


























1 19.4 14 44 Instable 15.3 47 83 Relatively stable 8 69 96 Relatively stable 8 23 63 Unstable
2 6.4 94 100 Stable 10.2 92 97 Stable 15.9 96 99 Stable 15 93 97 Stable
3 7.3 0 0 Instable 0.4 77 95 Stable 4.6 83 94 Stable 9.8 66 94 Relatively stable
4 18 47 87 Relatively stable 19.6 15 52 Instable 12.6 43 88 Relatively stable 12.5 33 77 Relatively stable
MS macular sensitivity
FS2 percentage of fixation points within the 2° circle
FS4 percentage of fixation points within the 4° circle
dB decibel
Fig. 3 Baseline and postoperative mfERG examinations in all treated subjects. The first order response density of mfERG examinations at baseline
and at successive time-points revealed a progressive increased foveal peak response in the treated eyes over the follow-up
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presence of natural lens in the treated eye. In addition, we
show the clinical results of a patient who presented BCVA
higher than 20/25 before injection.
Although this was a small series with a limited follow-
up interval, no major adverse effects, except the worsening
of the macular hole and the associated disruption of
photoreceptor inner segment–outer segment in the
patient 1, were encountered following intravitreal injection
of Ocriplasmin, specifically, no retinal tears, retinal
detachment, post-injection inflammation, acute severe
panretinal dysfunction. The development or worsening of
macular hole was the most frequent eye serious adverse
event reported in Ocriplasmin trials [1], with no signifi-
cant difference between treatment and control group. Un-
fortunately, in our treated patient with MH, in spite of
VMT release, MH enlarged and changed from stage 2
to stage 4. However, an improvement in visual function
and mfERG response was observed and may be due to
the increased activity of photoreceptors in the perile-
sional area (corresponding to ring 1 and 2) after the re-
lease of VMT.
Similarly to the findings on the patients receiving
Ocriplasmin injection in clinical trials and recent reports
of treated cases [3, 4, 14], we observed a decline in BCVA
after Ocriplasmin injection, followed by an improvement
of at least one ETDRS line, which started after VMT
resolution, even if associated with vitreous floaters and
photopsia. No other symptoms, e.g. the discromatop-
sia, which was reported in some cases by other authors
[3, 4, 14], were reported by our patients. Furthermore,
in our study, for the first time in the literature, we
evaluated the macular functionality through the study
of tests such as MP1 and mfERG for a six month
follow-up.
MP1 enabled to observe an improvement in fixation
stability, even if with stable macular sensitivity. The ana-
lysis of mfERG responses showed a significant increase
of N1 and P1 amplitudes after Ocriplasmin injection
(six-month follow-up). The mfERG waveforms originate
from cone photoreceptors and bipolar and Muller cells
respectively [15]. Hence, our findings, through the use of
mfERG, allow to highlight the functional improvement
of retinal layers, induced by the injection of Ocriplasmin.
Moreover, we compared the time course of visual acuity
and the responses of mfERG, also in relationship with
the time of the VMT release. This analysis showed that
there is a statistically significant correlation between the
resolution of the VMT, the onset of BCVA increase and of
improved mfERG responses. Therefore, the longitudinal
analysis shows that visual acuity changes are correlated
with the change in mfERG responses. Moreover, the
results of our study demonstrate that the morphological
resolution with the release of VMT does not coincide with
an immediate functional recovery. In fact, functional tests,
as mfERG and visual acuity measurement, also after VMT
release, improved progressively throughout the course of
follow-up. Probably, it takes longer to restore the architec-
ture of retinal layers and their functionality with respect
to VMT release. Limited evidence has been reported in
literature about the restoration time also after vitrectomy
for VMT release, however a recent meta-analysis demon-
strated a mean improvement of 0.28 LogMAR in BCVA
after vitrectomy [16], which is comparable with the mean
improvement in BCVA that we observed in our patients
with BCVA reduction (0.21 LogMAR). Moreover, the
follow-up time is usually longer than six months in the
studies investigating vitrectomy, suggesting that the
surgical procedure requires a longer time for restoration
of visual functionality.
Conclusions
Our study shows that Ocriplasmin was safe and effective in
the treatment of VMT not associated with MH, since it
leaded not only to a morphological recovery but mostly to
an improvement of macular functionality within a six-
month follow-up. However, the patients should be selected
carefully for Ocriplasmin treatment (e.g., absence of epiret-
inal membrane, adhesion diameter less than 1,500 μm,
presence of natural lens in the treated eye) and monitored
cautiously using SD-OCT and other functional techniques
(i.e., mfERG and MP1). However, the treatment of MH is
still challenging because of the risk of its enlargement even
Table 3 Longitudinal regression analysis of mfERG responses
Ring N1 implicit time N1 amplitude P1 implicit time P1 amplitude
β Std. Err. p-value β Std. Err. p-value β Std. Err. p-value β Std. Err. p-value
1 .074 .0467 .111 −1.344 .2415 <.001 -.238 .0548 <.001 2.558 .5020 <.001
2 -.227 .0541 <.001 -.576 .2467 .019 -.110 .0519 .034 1.093 .5034 .030
3 -.267 .0521 <.001 -.217 .2523 .389 -.225 .0565 <.001 .458 .5113 .371
4 -.178 .0534 .001 .016 .2534 .948 -.050 .0572 .380 .043 .5102 .933
5 -.264 .0500 <.001 -.049 .2546 .848 -.234 .0537 <.001 -.140 .5064 .782
6 -.191 .0465 <.001 .053 .2546 .835 -.106 .0577 .067 -.053 .5115 .918
Std. Err Standard Error
Significant p-value and related data (i.e, coefficient and standard error) are in bold
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in case of VMT release (primary endpoint) not associated
to hole closure (secondary endpoint). Further studies could
assess the improvement of visual function in the treat-
ment of VMT associated with MH by Ocriplasmin, also
in the case of non-closure of the macular lesion. Fi-
nally, follow-up visits should exceed 12 weeks after in-
jection, since long-term effects need to be investigated
in order to evaluate the safety and effectiveness of
Ocriplasmin.
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Additional file 1: Multifocal electroretinogram data. (XLSX 14 kb)
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